The latest financial statement is for the quarter ending 2026-03-31.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net income | 1,861 | 1,274 | 1,973 | 1,632 |
| Depreciation and amortization | 650 | 722 | 697 | 682 |
| Investment (gains) losses, net | 258 | -100 | 26 | 52 |
| Deferred income tax benefit | 60 | -500 | -118 | 76 |
| Gain on sale of businesses | 11 | -66 | 38 | 0 |
| Accounts receivable, net | -2,152 | -2,281 | 513 | 4,193 |
| Inventories | -1,507 | 1,706 | -334 | 791 |
| Reinsurance recoverable and other assets | -104 | 360 | 135 | 183 |
| Insurance liabilities | 739 | -415 | -40 | -76 |
| Pharmacy and other service costs payable | -4,570 | 31 | 842 | 860 |
| Accounts payable and accrued expenses and other liabilities | -988 | 3,654 | 163 | 154 |
| Other, net | -5 | -2 | -43 | -157 |
| Net cash provided by operating activities | 1,131 | 6,149 | 3,418 | -1,886 |
| Proceeds From Sale Of | 54 | 264 | 246 | 178 |
| Proceeds From Maturities Prepayments And Calls Of | 185 | 241 | 192 | 331 |
| Proceeds From Collection Of Loans | 2 | 25 | 108 | 5 |
| Other sales, maturities and repayments (primarily short-term and other long-term investments) | 426 | 228 | 225 | 100 |
| Payments To Acquire | 362 | 517 | 3,759 | 560 |
| Payments To Acquire Mortgage Notes | 39 | 0 | 55 | 28 |
| Other (primarily short-term and other long-term investments) | 557 | 350 | 305 | 286 |
| Property and equipment purchases, net | 267 | 322 | 278 | 285 |
| Acquisitions, net of cash acquired | - | 0 | 597 | - |
| Divestitures, net of cash sold | 20 | 638 | 0 | 0 |
| Renewable energy tax credit equity investments | 94 | 617 | 158 | 235 |
| Other, net | 5 | 10 | 6 | 17 |
| Net cash (used in) provided by investing activities | -637 | -420 | -4,387 | -797 |
| Deposits and interest credited to contractholder deposit funds | 39 | 39 | 39 | 38 |
| Withdrawals and benefit payments from contractholder deposit funds | 99 | 52 | 64 | 73 |
| Net change in short-term debt | -13 | -12 | -1,211 | 1,187 |
| Net proceeds on issuance of term loan | - | 0 | 1,999 | - |
| Repayment of term loan | - | 0 | 2,000 | - |
| Repayment of long-term debt | 550 | 2,554 | 43 | 900 |
| Net proceeds on issuance of long-term debt | - | -3 | 4,461 | 0 |
| Repurchase of common stock | 0 | 1,001 | 0 | 1,112 |
| Issuance of common stock | 57 | 25 | 37 | 72 |
| Common stock dividend paid | 417 | 396 | 402 | 401 |
| Other, net | -158 | -112 | -157 | -144 |
| Net cash used in financing activities | -1,141 | -4,066 | 2,659 | -1,333 |
| Effect of foreign currency rate changes on cash, cash equivalents and restricted cash | -9 | 2 | -5 | 26 |
| Net decrease in cash, cash equivalents and restricted cash | -656 | 1,665 | 1,685 | -3,990 |
| Cash, cash equivalents and restricted cash january 1, including held for sale assets | - | 2,860 | 4,545 | 555 |
| Cash, cash equivalents and restricted cash december 31, including held for sale assets | - | 1,665 | 1,685 | -3,990 |
| Cash and cash equivalents reclassified to assets of businesses held for sale | - | 0 | 0 | 0 |
| Cash, cash equivalents and restricted cash and cash equivalents january 1, | 7,736 | - | - | - |
| Cash, cash equivalents and restricted cash, end of year | 7,080 | 7,736 | 6,071 | 4,386 |
Cigna Group (CI)
Cigna Group (CI)